Levofloxacino Kabi (Levofloxacin Hemihydrate)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By preventing the resealing of DNA strands, it causes lethal double‑strand breaks, leading to rapid bacterial cell death across a broad spectrum of pathogens.

The dosage and infusion rate of Levofloxacino Kabi are determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and other clinical factors. No fixed regimen is provided here.

Levofloxacino Kabi is classified as pregnancy category C, indicating that risk to the fetus cannot be ruled out. It should be used only if the potential benefit justifies the potential risk. Use during breastfeeding is generally discouraged unless the benefit outweighs the risk to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling if needed) and import documentation.

Levofloxacino Kabi (levofloxacin) offers a broad Gram‑negative and Gram‑positive coverage similar to other fluoroquinolones but has a once‑daily dosing advantage in oral forms. Compared with agents like ciprofloxacin, levofloxacin often provides higher potency against respiratory pathogens and better lung tissue penetration, making it a preferred choice for pneumonia.

The product must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Prior to administration, allow the solution to reach room temperature if required, and inspect for particulate matter or discoloration before use.

Levofloxacino Kabi is given as an intravenous infusion. The infusion is typically administered over 30‑60 minutes, depending on the prescribed dose and patient tolerance. Administration should be performed by qualified healthcare personnel in a clinical setting.

Serious adverse events include tendon rupture or tendinitis, QT interval prolongation leading to arrhythmias, severe hypersensitivity reactions such as anaphylaxis, Clostridioides difficile‑associated diarrhea, peripheral neuropathy, and seizures. Patients should be monitored closely for any of these signs during therapy.

Levofloxacino Kabi is contraindicated in patients with a known hypersensitivity to levofloxacin or other fluoroquinolones. It should also be avoided in individuals with a history of tendon disorders related to fluoroquinolone use, uncontrolled QT prolongation, or those for whom the risks in pregnancy or lactation outweigh potential benefits.